EXCLUSIVE: Tiziana Life Sciences Plans To Develop Multiple Sclerosis Hopeful For Long COVID Patients

Tiziana Life Sciences Ltd TLSA plans to investigate intranasal foralumab for Long COVID.

What Happened: The work is supported by foralumab's well-established role in de-activating microglia cells, a key component in this disease's pathogenesis.

"We anticipate entering into a Phase 2a placebo-controlled clinical trial upon successful feedback from the FDA", commented Matthew Davis, Chief Medical Officer of Tiziana.

"The use of PET Scans will allow us to determine if intranasal foralumab will decrease activated microglia in patients with Long COVID after three months of administration," he added.

Also Read: Tiziana Life Sciences Posts Additional Clinical Improvements In Second Patient with Multiple Sclerosis.

The company plans to file an IND in 4Q 2023.

Why It Is Important: The estimated over 9 million people in the U.S. with Long COVID will cost the healthcare system a projected $2.6 trillion.

The company said the research using intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (SPMS), patients with COVID-19, and healthy volunteers showed a tolerogenic immune response induction by stimulating T regulatory cells while dampening CD3+ T effector function.

In short, intranasal foralumab modulates activated microglia while returning effector T cells to a naïve state.

Price Action: TLSA shares closed at $1.02 on Wednesday.